Overview We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to trick the bodys immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designe...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134950 | EDGAR | 90K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047921 | EDGAR | — |
| 2024-10-07 | 2024-06-30 | 0000950170-24-113321 | EDGAR | — |
| 2023-09-18 | 2023-06-30 | 0000950170-23-048588 | EDGAR | — |
| 2022-09-27 | 2022-06-30 | 0000950170-22-018865 | EDGAR | — |
| 2021-09-28 | 2021-06-30 | 0001564590-21-049235 | EDGAR | — |
| 2020-09-18 | 2020-06-30 | 0001564590-20-044019 | EDGAR | — |
| 2019-09-09 | 2019-06-30 | 0001213900-19-017497 | EDGAR | — |
| 2018-09-24 | 2018-06-30 | 0001213900-18-012876 | EDGAR | — |
| 2017-09-27 | 2017-06-30 | 0001213900-17-010055 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-281539 | EDGAR | 26K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108972 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072745 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127199 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059694 | EDGAR | — |
| 2024-02-14 | 2023-12-31 | 0000950170-24-015204 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062915 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020854 | EDGAR | — |
| 2023-02-14 | 2022-12-31 | 0000950170-23-002805 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023988 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0000950170-22-009809 | EDGAR | — |
| 2022-02-11 | 2021-12-31 | 0001564590-22-004688 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-29 | 0001193125-26-324174 | EDGAR | — |
| 2026-04-01 | 0001193125-26-135766 | EDGAR | 1K words |
| 2026-01-30 | 0001193125-26-031742 | EDGAR | — |
| 2025-12-10 | 0001193125-25-314302 | EDGAR | — |
| 2025-12-05 | 0001193125-25-309853 | EDGAR | — |
| 2025-11-25 | 0001193125-25-294581 | EDGAR | — |
| 2025-11-18 | 0001193125-25-286419 | EDGAR | — |
| 2025-11-14 | 0001193125-25-281522 | EDGAR | — |
| 2025-11-04 | 0001193125-25-263523 | EDGAR | — |
| 2025-11-03 | 0001193125-25-262562 | EDGAR | — |
332 total filings indexed. 300 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001498382 |
| Ticker | HURA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.tuhurabio.com |
| Listed | 2024-10-18 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/HURA (~200 tokens, structured JSON with cryptographic provenance)